When untreated, approximately 50% of NMOSD patients will become wheelchair-bound
and blind, and a third of them will die within
5 years of their first attack6. Hence, we strongly recommend
not interrupting immunosuppressive preventive treatment in NMOSD cases. The two
most common first-line treatment drugs in NMOSD are azathioprine and
rituximab. We suggest rituximab as the preferred initial therapy during
the pandemic because: